§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇲🇾Malaysia	🇪🇺European Union
Authority & dossier
Regulatory authority	NPRA	EMA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	Yes	Yes
Reliance pathway	Available	Available
Reference agencies	FDA (US), EMA, MHRA (UK), Health Canada +5	—
Lead pathway (timeline & fees) — Full Evaluation — New Drug Product (NCE / new biologic) · Centralised Procedure
Pathway name	Full Evaluation — New Drug Product (NCE / new biologic)	Centralised Procedure
Approval timeline	245–365 days	210–277 days
Application fee	MYR 1,000	EUR 358,800
Annual renewal	MYR 500	EUR 122,500
Local representative	Required	Required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	Yes
Local responsible person	Yes	Yes
RP role	PRHs must designate a registered pharmacist (under the Registration of Pharmacists Act 1951) as the responsible person for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) who is the contact for NPRA's Pharmacovigilance Section.	Qualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	2 designations	6 designations
Examples	Facilitated Registration Pathway (FRP), Conditional Registration / Public Health Emergency	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Variations classified per the DRGD into Major Variation (MaV — DCA approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation. Aligned with ASEAN Variation Guideline.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Drug registration is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety and labelling information.	Initial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	NPRA's Pharmacovigilance Section coordinates national ADR reporting (Malaysia is a member of the WHO Programme for International Drug Monitoring, Uppsala). PRHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. NPRA publishes safety alerts via MADRAC (Malaysian Adverse Drug Reactions Advisory Committee).	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–60 days	60–106 days
GCP standard	ICH E6(R2/R3) GCP; Malaysian Guideline for Good Clinical Practice	ICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Free pricing	Regulated
Reference pricing	No	Yes
HTA required	Yes	Yes
HTA body	MaHTAS — Malaysian Health Technology Assessment Section, Ministry of Health	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

MalaysiaNPRA
European UnionEMA

English submissions

MalaysiaYes
European UnionYes

CTD accepted

MalaysiaYes
European UnionYes

eCTD accepted

MalaysiaYes
European UnionYes

Reliance pathway

MalaysiaAvailable
European UnionAvailable

Reference agencies

MalaysiaFDA (US), EMA, MHRA (UK), Health Canada +5
European Union—

Lead pathway (timeline & fees) — Full Evaluation — New Drug Product (NCE / new biologic) · Centralised Procedure

Pathway name

MalaysiaFull Evaluation — New Drug Product (NCE / new biologic)
European UnionCentralised Procedure

Approval timeline

Malaysia245–365 days
European Union210–277 days

Application fee

MalaysiaMYR 1,000
European UnionEUR 358,800

Annual renewal

MalaysiaMYR 500
European UnionEUR 122,500

Local representative

MalaysiaRequired
European UnionRequired

Local manufacturing

MalaysiaNot required
European UnionNot required

GMP inspection

MalaysiaRequired
European UnionRequired

MAH & local presence

Local entity required

MalaysiaYes
European UnionYes

Local responsible person

MalaysiaYes
European UnionYes

RP role

MalaysiaPRHs must designate a registered pharmacist (under the Registration of Pharmacists Act 1951) as the responsible person for the licensed premises, and a Qualified Person for Pharmacovigilance (QPPV) who is the contact for NPRA's Pharmacovigilance Section.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Malaysia2 designations
European Union6 designations

Examples

MalaysiaFacilitated Registration Pathway (FRP), Conditional Registration / Public Health Emergency
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

MalaysiaVariations classified per the DRGD into Major Variation (MaV — DCA approval), Minor Variation (MiV-PA prior approval, MiV-N notification) and Administrative Variation. Aligned with ASEAN Variation Guideline.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

MalaysiaDrug registration is valid for 5 years and must be renewed before expiry, with up-to-date CMC, safety and labelling information.
European UnionInitial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

MalaysiaNPRA's Pharmacovigilance Section coordinates national ADR reporting (Malaysia is a member of the WHO Programme for International Drug Monitoring, Uppsala). PRHs must submit PSURs aligned to ICH E2C(R2), report serious ADRs within statutory timelines, and maintain a Risk Management Plan (RMP) for new active substances. NPRA publishes safety alerts via MADRAC (Malaysian Adverse Drug Reactions Advisory Committee).
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

MalaysiaAvailable
European UnionAvailable

Compassionate Use

MalaysiaAvailable
European UnionAvailable

Emergency Import

MalaysiaAvailable
European UnionAvailable

Parallel Import

MalaysiaNot permitted
European UnionPermitted

Clinical trials

CTA approval

MalaysiaRequired
European UnionRequired

Ethics approval

MalaysiaYes
European UnionYes

CTA timeline

Malaysia30–60 days
European Union60–106 days

GCP standard

MalaysiaICH E6(R2/R3) GCP; Malaysian Guideline for Good Clinical Practice
European UnionICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

MalaysiaFree pricing
European UnionRegulated

Reference pricing

MalaysiaNo
European UnionYes

HTA required

MalaysiaYes
European UnionYes

HTA body

MalaysiaMaHTAS — Malaysian Health Technology Assessment Section, Ministry of Health
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)